Search
Estrone sulfate
go.drugbank.com/drugs/DB04574ApprovedEstrone sulfate (as estropipate) is a form of estrogen.
αAβ–Gas6
go.drugbank.com/drugs/DB17069ExperimentalIt is made of a single chain variable fragment (scFv) of an Amyloid β (Aβ)-targeting monoclonal antibody fused with a truncated receptor binding domain of growth arrest-specific 6 (Gas6), which is a ligand … αAβ–Gas6 is a chimeric fusion protein being investigated in preclinical studies as an immunotherapeutic agent for Alzheimer's disease (AD).
Quinine
go.drugbank.com/drugs/DB00468ApprovedInvestigationalAn alkaloid derived from the bark of the cinchona tree. … It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis.
Plozalizumab
go.drugbank.com/drugs/DB12520InvestigationalThe recruitment of macrophages to the arterial wall is believed to be a critical step in the development of atherosclerosis. … Preclinical studies suggest that CCR2 plays an important role in the trafficking of monocytes and macrophages to sites of inflammation.
Sirna-027
go.drugbank.com/drugs/DB05896InvestigationalSirna-027 is a chemically modified short interfering RNA(siRNA) targeting Vascular Endothelial Growth Factor Receptor-1(VEGFR-1). … VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway. Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails.
Crotalus atrox antivenin
go.drugbank.com/drugs/DB13892ApprovedEach year it is estimated there are 45,000 snakebites in the US and 300,000 to 400,000 bites worldwide. About 8000 of these snakebites involve venomous snake species. The majority of people bitten are males and about 50% occur in the age...
SC-236
go.drugbank.com/drugs/DB14059ExperimentalSC-236 is a potent, selective, orally active inhibitor of cyclooxygenase-2 (COX-2) [L2964] that has been studied in cancer therapy [A33375], lower back pain [A33376], and inflammation [A33373], [A33374
Regdanvimab
go.drugbank.com/drugs/DB16405ApprovedWithdrawnTrials investigating the use of regdanvimab as a therapeutic candidate for the treatment of COVID-19 began in mid-2020. … Regdanvimab (CT-P59) is a recombinant human IgG1 monoclonal antibody directed at the receptor binding domain (RBD) of the SARS-CoV-2 spike protein.
Mexiletine
go.drugbank.com/drugs/DB00379ApprovedInvestigationalAntiarrhythmic agent pharmacologically similar to lidocaine. It may have some anticonvulsant properties.
Clofibrate
go.drugbank.com/drugs/DB00636ApprovedWithdrawnA fibric acid derivative used in the treatment of hyperlipoproteinemia type III and severe hypertriglyceridemia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p986)